Entera Bio

Entera Bio R&D / Revenue

The R&D to Revenue Ratio of Entera Bio (ENTX) as of Nov 22, 2026 is 14,295.24 %. In the previous year, R&D to Revenue Ratio was 2,485.64 % — a change of 475.11% (higher).

R&D / Revenue

14,295.24 %

YoY

475.11%

Last updated:

R&D to Revenue Ratio of Entera Bio is 2025 14,295.24 % . R&D to Revenue Ratio of Entera Bio was 2024 2,485.64 % . It decreases by 475.11% higher compared to the previous year.

The Entera Bio R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2018
1,703.60 USD
Jan 1, 2019
2,949.58 USD
Jan 1, 2020
1,752.88 USD
Jan 1, 2021
1,185.81 USD
Jan 1, 2022
4,364.18 USD
Jan 1, 2023
31,814.29 USD
Jan 1, 2024
2,485.64 USD
Jan 1, 2025
14,295.24 USD
The Entera Bio R&D / Revenue history
YEARR&D / RevenueYoY
14,295.24 %+475.11%
2,485.64 %-92.19%
31,814.29 %+628.99%
4,364.18 %+268.03%
1,185.81 %-32.35%
1,752.88 %-40.57%
2,949.58 %+73.14%
1,703.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

R&D to Revenue Ratio of Entera Bio is 14,295.24 % in 2025.

R&D to Revenue Ratio of Entera Bio changed from 2,485.64 % to 14,295.24 %, representing a 475.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Entera Bio

All Key Metrics — Entera Bio